Detalhe da pesquisa
1.
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
N Engl J Med
; 386(4): 316-326, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081280
2.
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
Ann Rheum Dis
; 82(7): 901-910, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36931693
3.
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Ann Rheum Dis
; 82(3): 331-343, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36600185
4.
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
Ann Rheum Dis
; 82(1): 119-129, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36137735
5.
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Ann Rheum Dis
; 80(8): 1004-1013, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33906853
6.
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
N Engl J Med
; 377(16): 1525-1536, 2017 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045207
7.
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
N Engl J Med
; 377(16): 1537-1550, 2017 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045212
8.
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Ann Rheum Dis
; 79(11): 1400-1413, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32759265
9.
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
Ann Rheum Dis
; 82(4): 575-577, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720582
10.
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
BMC Dermatol
; 16(1): 15, 2016 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27716172
11.
Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir.
HIV Clin Trials
; 16(5): 170-7, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26365498
12.
Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.
HIV Clin Trials
; 15(5): 209-17, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25350959
13.
A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV.
Ann Hepatol
; 13(4): 364-75, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24927607
14.
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
Arthritis Rheumatol
; 2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38481002
15.
Microstructure and Properties of Ti-Zr-Mo Alloys Fabricated by Laser Directed Energy Deposition.
Materials (Basel)
; 16(3)2023 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36770060
16.
Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis.
ACR Open Rheumatol
; 5(12): 632-643, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37775977
17.
Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial.
Rheumatol Ther
; 10(4): 1001-1020, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37331992
18.
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance.
Ther Adv Musculoskelet Dis
; 15: 1759720X231201047, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37942277
19.
Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.
RMD Open
; 9(1)2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720560
20.
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Clin Rheumatol
; 41(2): 499-511, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34510295